JP2021169510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021169510A5 JP2021169510A5 JP2021118471A JP2021118471A JP2021169510A5 JP 2021169510 A5 JP2021169510 A5 JP 2021169510A5 JP 2021118471 A JP2021118471 A JP 2021118471A JP 2021118471 A JP2021118471 A JP 2021118471A JP 2021169510 A5 JP2021169510 A5 JP 2021169510A5
- Authority
- JP
- Japan
- Prior art keywords
- fulvestrant
- suspension
- microns
- administration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 62
- 229960002258 fulvestrant Drugs 0.000 claims 54
- 239000000725 suspension Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 9
- 229940087861 faslodex Drugs 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000007924 injection Substances 0.000 claims 8
- 238000010255 intramuscular injection Methods 0.000 claims 8
- 239000007927 intramuscular injection Substances 0.000 claims 8
- 239000003381 stabilizer Substances 0.000 claims 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 7
- 229940068968 polysorbate 80 Drugs 0.000 claims 7
- 229920000053 polysorbate 80 Polymers 0.000 claims 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 6
- 229930195725 Mannitol Natural products 0.000 claims 6
- 239000000594 mannitol Substances 0.000 claims 6
- 235000010355 mannitol Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 229920003072 Plasdone™ povidone Polymers 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 229920003078 Povidone K 12 Polymers 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000003792 electrolyte Substances 0.000 claims 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920002507 Poloxamer 124 Polymers 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920003079 Povidone K 17 Polymers 0.000 claims 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940093448 poloxamer 124 Drugs 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 229950003429 sorbitan palmitate Drugs 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023086732A JP2023109959A (ja) | 2016-05-06 | 2023-05-26 | フルベストラント配合物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US62/332,842 | 2016-05-06 | ||
| US201662420555P | 2016-11-10 | 2016-11-10 | |
| US62/420,555 | 2016-11-10 | ||
| JP2019510578A JP2019516789A (ja) | 2016-05-06 | 2017-05-05 | フルベストラント配合物およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510578A Division JP2019516789A (ja) | 2016-05-06 | 2017-05-05 | フルベストラント配合物およびその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086732A Division JP2023109959A (ja) | 2016-05-06 | 2023-05-26 | フルベストラント配合物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021169510A JP2021169510A (ja) | 2021-10-28 |
| JP2021169510A5 true JP2021169510A5 (https=) | 2022-01-06 |
| JP7312523B2 JP7312523B2 (ja) | 2023-07-21 |
Family
ID=58709642
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510578A Pending JP2019516789A (ja) | 2016-05-06 | 2017-05-05 | フルベストラント配合物およびその使用方法 |
| JP2021118471A Active JP7312523B2 (ja) | 2016-05-06 | 2021-07-19 | フルベストラント配合物およびその使用方法 |
| JP2023086732A Pending JP2023109959A (ja) | 2016-05-06 | 2023-05-26 | フルベストラント配合物およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510578A Pending JP2019516789A (ja) | 2016-05-06 | 2017-05-05 | フルベストラント配合物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023086732A Pending JP2023109959A (ja) | 2016-05-06 | 2023-05-26 | フルベストラント配合物およびその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (https=) |
| EP (1) | EP3452011A1 (https=) |
| JP (3) | JP2019516789A (https=) |
| KR (1) | KR102438425B1 (https=) |
| CN (1) | CN109310621A (https=) |
| AU (2) | AU2017261321B2 (https=) |
| CA (1) | CA3022834A1 (https=) |
| CO (1) | CO2018013257A2 (https=) |
| IL (2) | IL285928B2 (https=) |
| MA (1) | MA44862A (https=) |
| MX (2) | MX2018013414A (https=) |
| MY (1) | MY205661A (https=) |
| UA (1) | UA125514C2 (https=) |
| WO (1) | WO2017193048A1 (https=) |
| ZA (1) | ZA201807031B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP3706719A1 (en) | 2017-11-08 | 2020-09-16 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| CN114504551B (zh) * | 2020-11-16 | 2024-01-02 | 北京厚燊维康科技有限责任公司 | 可用于光动力治疗或诊断的制剂 |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| JP2024545690A (ja) * | 2021-12-20 | 2024-12-10 | サムヤン、ホールディングス、コーポレーション | 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| WO2001087262A2 (en) | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Stabilized steroidal suspension |
| PL367624A1 (en) * | 2001-07-07 | 2005-03-07 | Astrazeneca Ab | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| CA2575906C (en) * | 2004-08-04 | 2014-04-15 | Camurus Ab | Compositions forming non-lamellar dispersions |
| KR101429774B1 (ko) | 2005-05-09 | 2014-10-02 | 바이오스피어 메디칼 에스.에이. | 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및방법 |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| MX2011013797A (es) | 2009-06-18 | 2012-01-30 | Abbott Lab | Suspension de farmaco estable de nanoparticula. |
| WO2011022861A1 (zh) * | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| WO2011011978A1 (zh) * | 2009-07-31 | 2011-02-03 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
| WO2012021791A2 (en) | 2010-08-13 | 2012-02-16 | Scidose Llc | Aqueous formulation with improved stability |
| CN103221052A (zh) | 2010-09-16 | 2013-07-24 | 施摩达生物技术有限公司 | 氟维司群组合物及使用方法 |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| EP2661281B1 (en) | 2011-01-09 | 2021-03-10 | ANP Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| EP2711010B1 (en) * | 2011-05-20 | 2018-10-31 | Capital, Business Y Gestión De Finanzas, S.L | Pharmaceutical composition |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业（深圳）有限公司 | 资料存储器固定装置 |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| CA2869377C (en) | 2012-04-09 | 2022-11-08 | Scidose, Llc | Fulvestrant formulations |
| WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| WO2015033302A2 (en) * | 2013-09-06 | 2015-03-12 | Salah Uddin Ahmed | Fulvestrant compositions |
| JP2016536282A (ja) * | 2013-10-03 | 2016-11-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| JP6235755B2 (ja) | 2014-07-02 | 2017-11-22 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 高いカーゴ対サーファクタント比を有するサーファクタント除去ミセル組成物 |
| CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
- 2017-05-05 CA CA3022834A patent/CA3022834A1/en active Pending
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/en not_active Ceased
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/en active Pending
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021169510A5 (https=) | ||
| JP5661640B2 (ja) | 薬学的懸濁物 | |
| CN1125653C (zh) | 含有伏利康唑的药物制剂 | |
| JP2010524992A (ja) | プロスタグランジン類を含有する眼科用水中油型エマルジョン | |
| JP2012511009A5 (https=) | ||
| RU2012101818A (ru) | Наноструктурированное основание силденафила, его фармацевтически приемлемые соли и со-кристаллы, их композиции, способ их получения и содержащие их фармацевтические композиции | |
| JP2013056948A (ja) | 安定なプロスタグランジン含有組成物 | |
| WO1999033490A1 (fr) | Compositions medicinales a liberation prolongee | |
| EA023208B1 (ru) | Фармацевтические композиции, которые содержат имидазохинолин(амины) и их производные, пригодные для местного введения | |
| JP2023109959A5 (https=) | ||
| CN102802619A (zh) | 眼科用组合物 | |
| PT1819362E (pt) | Formulações tópicas de nepafenac | |
| JP2020073564A5 (https=) | ||
| JP2002356420A (ja) | 安定な水性液剤 | |
| EP2205215A2 (en) | Docetaxel injectable composition, being absolutely free of ethanol | |
| WO2006132342A1 (ja) | ロフルミラスト点眼液 | |
| KR102638866B1 (ko) | 사이클로스포린 및 멘톨 함유 나노 에멀젼 점안 조성물 및 그의 제조 방법 | |
| JP2001048807A (ja) | 難溶性薬物を水に溶解してなる製剤 | |
| JP5420877B2 (ja) | 眼科用剤 | |
| JP2009504634A (ja) | プロポフォールを含む水性麻酔剤組成物 | |
| JP4524559B2 (ja) | 眼科用組成物及びビタミンａ類の安定化方法 | |
| WO2001087303A1 (en) | Aqueous liquid preparation | |
| JP2006527764A (ja) | ジアゼパムを含有する経鼻マイクロエマルジョン | |
| KR20140022900A (ko) | 2종의 상이한 점도 증강제를 포함하는 점도 증강 시스템을 갖는 안과 조성물 | |
| JP2007016024A (ja) | ロフルミラスト点眼液 |